TG-100435
TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with Ki of 13 to 64 nM for Src, Lyn, Abl, Yes, Lck, and EphB4. TG-100435 plays an important role in cancer research.
For research use only. We do not sell to patients.
- CAS No.: 867330-68-5
- Formula: C26H25Cl2N5O
- Molecular Weight:494.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.9 μM
Compound: 3
|
Antitumor activity against A549 cells
Antitumor activity against A549 cells
|
[PMID: 17113292] |
| COLO 205 | IC50 |
2.5 μM
Compound: 3
|
Antitumor activity against Colo205 cells
Antitumor activity against Colo205 cells
|
[PMID: 17113292] |
| CT26 | IC50 |
0.75 μM
Compound: 3
|
Antitumor activity against mouse CT26 cells
Antitumor activity against mouse CT26 cells
|
[PMID: 17113292] |
| HT-29 | IC50 |
>5 μM
Compound: 3
|
Antitumor activity against HT29 cells
Antitumor activity against HT29 cells
|
[PMID: 17113292] |
| K562 | IC50 |
0.215 μM
Compound: 3
|
Antitumor activity against K562 cells
Antitumor activity against K562 cells
|
[PMID: 17113292] |
| MCF7 | IC50 |
0.085 μM
Compound: 3
|
Antitumor activity against MCF7 cells
Antitumor activity against MCF7 cells
|
[PMID: 17113292] |
| MDA-MB-231 | IC50 |
0.24 μM
Compound: 3
|
Antitumor activity against MDA-MB-231 cells
Antitumor activity against MDA-MB-231 cells
|
[PMID: 17113292] |
| MOLT-4 | IC50 |
0.25 μM
Compound: 3
|
Antitumor activity against Molt4 cells
Antitumor activity against Molt4 cells
|
[PMID: 17113292] |
Chemical Information
-
CAS No. 867330-68-5
-
Molecular Weight 494.42
-
Formula C26H25Cl2N5O
-
SMILES
ClC1=C(C2=CC3=C(C(C)=C2)N=C(NC4=CC=C(C=C4)OCCN5CCCC5)N=N3)C(Cl)=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Steven X Hu, et al. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine). Comparative Study Drug Metab Dispos. 2007 Jun;35(6):929-36. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)